Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: a commentary on "PARP Inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy".
作者信息
Pacher Pal
机构信息
Section on Oxidative Stress Tissue Injury, Laboratory of Physiological Studies, National Institutes of Health/NIAAA, 5625 Fishers Lane, Room 2-N17, MSC 9413, Bethesda, MD 20892-9413, USA.
出版信息
Free Radic Biol Med. 2008 Mar 15;44(6):969-71. doi: 10.1016/j.freeradbiomed.2007.12.020. Epub 2008 Jan 14.
Abstract
摘要
相似文献
1
Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: a commentary on "PARP Inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy".
Free Radic Biol Med. 2008 Mar 15;44(6):969-71. doi: 10.1016/j.freeradbiomed.2007.12.020. Epub 2008 Jan 14.
2
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Free Radic Biol Med. 2008 Mar 15;44(6):972-81. doi: 10.1016/j.freeradbiomed.2007.09.013. Epub 2007 Oct 3.
3
PARP inhibitors attenuate chemotherapy-induced painful neuropathy.
J Peripher Nerv Syst. 2012 Sep;17(3):324-30. doi: 10.1111/j.1529-8027.2012.00413.x.
4
Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
Diabetologia. 2004 Apr;47(4):710-7. doi: 10.1007/s00125-004-1356-0.
5
Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation.
Exp Clin Endocrinol Diabetes. 2012 Mar;120(3):132-8. doi: 10.1055/s-0031-1291248. Epub 2011 Oct 21.
6
New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}.
Endocrinology. 2010 Jun;151(6):2547-55. doi: 10.1210/en.2009-1342. Epub 2010 Mar 31.
7
Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy.
Diabetes. 2005 May;54(5):1514-22. doi: 10.2337/diabetes.54.5.1514.
8
Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice.
Int J Mol Med. 2011 Oct;28(4):629-35. doi: 10.3892/ijmm.2011.709. Epub 2011 May 23.
9
Pain-related changes in cutaneous innervation of patients suffering from bortezomib-induced, diabetic or chronic idiopathic axonal polyneuropathy.
Brain Res. 2020 Mar 1;1730:146621. doi: 10.1016/j.brainres.2019.146621. Epub 2020 Jan 9.
10
A pain in the skin. Regenerating nerve sprouts are distinctly associated with ongoing burning pain in patients with diabetes.
Eur J Pain. 2018 Nov;22(10):1727-1734. doi: 10.1002/ejp.1259. Epub 2018 Jul 9.
引用本文的文献
1
Lysophosphatidic Acid Receptor 1- and 3-Mediated Hyperalgesia and Hypoalgesia in Diabetic Neuropathic Pain Models in Mice.
Cells. 2020 Aug 16;9(8):1906. doi: 10.3390/cells9081906.
2
Neuropathic Pain: Delving into the Oxidative Origin and the Possible Implication of Transient Receptor Potential Channels.
Front Physiol. 2018 Feb 14;9:95. doi: 10.3389/fphys.2018.00095. eCollection 2018.
3
Mechanisms of disease: the oxidative stress theory of diabetic neuropathy.
Rev Endocr Metab Disord. 2008 Dec;9(4):301-14. doi: 10.1007/s11154-008-9104-2.
本文引用的文献
1
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Free Radic Biol Med. 2008 Mar 15;44(6):972-81. doi: 10.1016/j.freeradbiomed.2007.09.013. Epub 2007 Oct 3.
2
Diabetic neuropathy--a review.
Nat Clin Pract Neurol. 2007 Jun;3(6):331-40. doi: 10.1038/ncpneuro0504.
3
Nitrosative stress and peripheral diabetic neuropathy in leptin-deficient (ob/ob) mice.
Exp Neurol. 2007 Jun;205(2):425-36. doi: 10.1016/j.expneurol.2007.03.019. Epub 2007 Mar 27.
4
Nitric oxide and peroxynitrite in health and disease.
Physiol Rev. 2007 Jan;87(1):315-424. doi: 10.1152/physrev.00029.2006.
5
The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity.
Diabetes. 2006 Dec;55(12):3335-43. doi: 10.2337/db06-0885.
6
Remote neurotrophic support of epidermal nerve fibres in experimental diabetes.
Diabetologia. 2006 May;49(5):1081-8. doi: 10.1007/s00125-006-0169-8. Epub 2006 Mar 10.
7
Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme.
Antioxid Redox Signal. 2005 Nov-Dec;7(11-12):1568-80. doi: 10.1089/ars.2005.7.1568.
8
Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications.
Antioxid Redox Signal. 2005 Nov-Dec;7(11-12):1543-52. doi: 10.1089/ars.2005.7.1543.
9
The pathobiology of diabetic complications: a unifying mechanism.
Diabetes. 2005 Jun;54(6):1615-25. doi: 10.2337/diabetes.54.6.1615.
10
Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients.
Diabetes Care. 2004 Aug;27(8):1974-9. doi: 10.2337/diacare.27.8.1974.
Zotero 插件